Pharmacological Approaches for Nonalcoholic Fatty Liver Disease

• Main Authors: Ionică Floriana Elvira, Negreș Simona, Bejenaru Ludovic, Bejenaru Cornelia, Chiriță Cornel
• Format: Article
• Language: English
• Published: Sciendo 2016-09-01
• Series: Romanian Journal of Diabetes Nutrition and Metabolic Diseases
• Subjects: nonalcoholic fatty liver disease; insulin sensitizers; incretin-based therapies; farnesoid X receptor agonists; caspase inhibition
• Online Access: http://www.degruyter.com/view/j/rjdnmd.2016.23.issue-3/rjdnmd-2016-0037/rjdnmd-2016-0037.xml?format=INT

Background and aims: Nonalcoholic fatty liver disease (NAFDL) is a multifactorial condition with a wide spectrum of histological severities, from asymptomatic hepatic steatosis to nonalcoholic steatohepatitis (NASH) with or without fibrosis. NAFLD is highly common and potentially serious in children and adolescents and affects approximately one third of the general population. It is closely associated with obesity, insulin resistance and dyslipidemia. NASH is a histological diagnosis and has a great significance because it can progress to cirrhosis, liver failure, and hepatocellular carcinoma (HCC), and is associated with both increased cardiovascular and liver related mortality. The purpose of this review is to summarize the evidence for current potential therapies of NAFLD.